Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

PURPOSE: Standard frontline treatment of patients with metastatic renal cell carcinoma currently includes sunitinib. A barrier to long-term treatment with sunitinib includes the development of significant adverse effects, including diarrhea, hand-foot syndrome (HFS), and fatigue. This trial assessed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Jonasch, Eric, Slack, Rebecca S., Geynisman, Daniel M., Hasanov, Elshad, Milowsky, Matthew I., Rathmell, W. Kimryn, Stovall, Summer, Juarez, Donna, Gilchrist, Troy R., Pruitt, Lisa, Ornstein, Moshe C., Plimack, Elizabeth R., Tannir, Nizar M., Rini, Brian I.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804828/
https://ncbi.nlm.nih.gov/pubmed/29641297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.77.1485
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados